BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15083603)

  • 1. Amediplase. Menarini.
    Doggrell SA
    Curr Opin Investig Drugs; 2004 Mar; 5(3):344-7. PubMed ID: 15083603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amediplase: CGP 42935, K2tu-PA, MEN 9036.
    BioDrugs; 2002; 16(5):378-9. PubMed ID: 12408743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ideal fibrinolytic: can drug design improve clinical results?
    Van de Werf FJ
    Eur Heart J; 1999 Oct; 20(20):1452-8. PubMed ID: 10493843
    [No Abstract]   [Full Text] [Related]  

  • 4. Clot penetration and fibrin binding of amediplase,a chimeric plasminogen activator (K2 tu-PA).
    Rijken DC; Barrett-Bergshoeff MM; Jie AF; Criscuoli M; Sakharov DV
    Thromb Haemost; 2004 Jan; 91(1):52-60. PubMed ID: 14691568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombolytic agents.
    Collen D; Lijnen HR
    Thromb Haemost; 2005 Apr; 93(4):627-30. PubMed ID: 15841305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective enzyme thrombolytic composition on the basis of wild-type and chemically modified plasminogen activators.
    Maksimenko AV; Tischenko EG; Petrov AD; Petrova ML
    Ann N Y Acad Sci; 1996 Oct; 799():146-50. PubMed ID: 8958085
    [No Abstract]   [Full Text] [Related]  

  • 7. [Development of the high effective thrombolytic agents with molecular biological technique].
    Wu HZ; Li JZ
    Zhonghua Nei Ke Za Zhi; 1993 Jan; 32(1):11-3. PubMed ID: 8404311
    [No Abstract]   [Full Text] [Related]  

  • 8. [Biochemical, pharmacologic and clinical properties of new thrombolytic agents].
    Gulba DC
    Internist (Berl); 1996 Jun; 37(6):552-66. PubMed ID: 8767988
    [No Abstract]   [Full Text] [Related]  

  • 9. [Coronary thrombolytic agents and their characteristics].
    Yoshinaga M; Kambara H
    Nihon Rinsho; 1994 Jul; 52 Suppl(Pt 1):775-81. PubMed ID: 12436615
    [No Abstract]   [Full Text] [Related]  

  • 10. [Combined thrombolysis by pharmacokinetically different plasminogen activators].
    Maksimenko AV
    Bioorg Khim; 1998 May; 24(5):376-80. PubMed ID: 9661792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI).
    GuimarĂ£es AH; Barrett-Bergshoeff MM; Criscuoli M; Evangelista S; Rijken DC
    Thromb Haemost; 2006 Sep; 96(3):325-30. PubMed ID: 16953274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards the development of improved thrombolytic agents.
    Lijnen HR; Collen D
    Br J Haematol; 1991 Mar; 77(3):261-6. PubMed ID: 1901494
    [No Abstract]   [Full Text] [Related]  

  • 13. [Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction].
    Czyrski J
    Wiad Lek; 1989 Apr; 42(7):450-2. PubMed ID: 2516932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Lubbers NL; Nelson RA; Henkin J
    Thromb Haemost; 1997 May; 77(5):1025-30. PubMed ID: 9184422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 16. Single-chain urokinase-type plasminogen activator: mechanism of action and thrombolytic properties.
    Lijnen HR; Stump DC; Collen DC
    Semin Thromb Hemost; 1987 Apr; 13(2):152-9. PubMed ID: 3114883
    [No Abstract]   [Full Text] [Related]  

  • 17. Serine-proteases as plasminogen activators in terms of fibrinolysis.
    Flemmig M; Melzig MF
    J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newer thrombolytic drugs for acute myocardial infarction.
    Reddy DS
    Indian J Exp Biol; 1998 Jan; 36(1):1-15. PubMed ID: 9536645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thrombolytic agents].
    Nagao T
    Nihon Rinsho; 2014 Jul; 72(7):1254-7. PubMed ID: 25163317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fibrinolytic agents--who benefits when?].
    Weichert W; Seifried E
    Ther Umsch; 1995 Oct; 52(10):652-60. PubMed ID: 7482376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.